Answers are grounded in this paper and cite their sources.
Mycophenolic acid (MPA) is an immunosuppressive agent available either as an ester prodrug or as a sodium salt. Mycophenolate mofetil (MMF) is the 2-morpholinoethyl ester prodrug of MPA formulated to improve its bioavailability [1,2]. Mycophenolate sodium is a delayed-release formulation that delivers MPA to the small intestine without being released into the stomach. MPA is indicated as a prophylactic agent in patients receiving allogeneic renal, cardiac, or hepatic transplants. It is a noncompetitive, selective, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). IMPDH is an important rate-limiting enzyme involved in purine synthesis, which converts inosine monophosphate (IMP) to guanosine monophosphate (GMP) [3-5].
No takes yet. Share an insight, caveat, or question.
Lamba et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: